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Irradiation of malignant exophthalmos 
in the course of Graves Basedow disease
Aneta L. ZYGULSKA1, Barbara KOWALSKA2
SUMMARY
AIM: To present results of irradiation of ophthalmopathy in the course of Graves-Basedow disease 
performed in the Radiotherapy Laboratory in University Children’s Hospital in Cracow by staff of the 
Oncology Clinic, Collegium Medicum Jagiellonian University (CM UJ). 
MATERIAL AND METHOD: During the period of 2000–2003 therapeutic irradiation of the retrobulbar 
area was performed in 121 patients with malignant exophthalmos using a total dose of 20 Gy/ 10 
fractions of 6 MV photonic beam in the Radiotherapy Laboratory in University Children’s Hospital in 
Cracow. Execution of the treatment plan was controlled by in vivo dose measurements using semicon-
ducting detectors, MOSFET type. Radiotherapy was preceded by intravenous corticosteroid therapy 
(Solu Medrol) with a dose of 2g/ week for 4 weeks. 
RESULTS: During the irradiation treatment 9 patients (7.4%) developed an acute post-radiation reac-
tion of transient character. Ophthalmological control examination revealed an improvement in 97 pa-
tients (80.2%) in the form of reduction or total regression of ophthalmopathy symptoms; in 21 other 
patients (17.3%) stabilization was noted and progression in 3 (2.5%). 
CONCLUSIONS: Radiotherapy is a well-tolerated method of ophthalmopathy treatment in the course of 
Graves-Basedow disease. Effi cacy of radiotherapy as an exclusive method of malignant exophthalmos 
treatment seems to be lower in comparison to irradiation combined with corticosteroid therapy.
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INTRODUCTION
Radiotherapy has been for many years one of 
the methods used in treatment of ophthalmopa-
thy occurring in the course of Graves-Basedow 
disease [1, 2]. The aim of this therapeutic pro-
cedure is fi rst of all to inhibit disease progres-
sion and reduce or eliminate the functional im-
pairment of the organ of sight and to improve 
the patient’s appearance. It is signifi cant that 
ophthalmopathy irradiation is accompanied by 
few side effects [3, 4, 5, 6, 7, 8, 9, 10].
The disease is a result of an autoimmuno-
logical process. Activated suppressor T lym-
phocytes infi ltrate the muscles moving the 
eyeball which leads to their thickening. Some 
cytokines stimulate orbital fi broblasts to syn-
thesise glycosaminoglycans that absorb water 
in the retrobulbar area [11, 12, 13, 14, 15, 16, 
17, 18]. As a result of this the patient starts to 
develop ophthalmic symptoms involving peri-
orbital soft tissues, eyelids, oculomotor mus-
cles and even optic nerves [19, 20, 21].
AIM
Diagnosis of ophthalmopathy is mainly based 
on clinical data. The aim of ophthalmological 
examination is to assess the state of eyelids, 
conjunctivas, exophthalmos, oculomotor mus-
cle dysfunction, cornea and visual acuity [22, 
23, 24]. In the case of euthyreosis an imaging 
examination of orbital regions (computed to-
mography – CT, magnetic resonance – MR) 
is performed to fi nd the cause of ophthalmic 
symptoms [25, 26, 27, 28, 29, 30, 31, 32, 33].
MATERIAL AND METHOD
Patients with infi ltrative ophthalmopathy in 
the course of Graves-Basedow disease are 
qualifi ed in our centre for irradiation treat-
ment according to the following criteria:
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1) euthyreosis assessed on the basis of TSH, 
T3, T4, FT4 levels, 
2) qualifi cation for therapy by a consulting 
ophthalmologist, i.e. ophthalmic symptoms 
according to the Werner modifi ed scale cor-
respond at least to 3c class [34, 35], 
3) CT of the orbits shows characteristic fea-
tures of Graves-Basedow disease (thickening 
of straight muscles in both orbits which may 
be accompanied by increased fat tissue, dam-
aged optic nerve and enlargement of the lac-
rimal gland), 
4) patient’s consent to proposed treatment.
Patients were initially treated with gluco-
corticosteroids (Solu Medrol) administered 
intravenously – 2g per week for 4 weeks in the 
Endocrinology Clinic CM UJ. Ambulatory ir-
radiation of retrobulbar areas was performed 
in the Radiotherapy Laboratory in University 
Children’s Hospital in Cracow by staff of the 
Oncology Clinic, CM UJ. Overall during the 
period from January 2000 to December 2003 
121 patients were irradiated (91 women – 
75.2% and 30 men – 24.8%). Mean age was 55.1 
(age range: 32 – 85).
Before the treatment initiation an individu-
al plexiglass mask was created for all the pa-
tients which allowed the limits of irradiation 
fi elds to be reconstructed. CT examination of 
the orbits was performed in all the patients for 
therapy planning purposes. Due to the need 
to precisely defi ne the distance between irra-
diation fi eld margins and lenses, the distance 
between tomography layers was 3 mm. Irra-
diation technique was based on exposing the 
retrobulbar area to the effect of two opposite, 
isocentric beams which would create one, com-
mon (fl at) line from the lens direction (Fig. 1) 
[36, 37]. The area of extraorbital structures 
was protected by shields made of Wood’s al-
loy. Dimensions of the irradiation fi eld were 
within limits of 4 cm x 5 cm. To irradiate the 
retrobulbar areas a photon beam (energy of 
6 MV) emitted by a Mevatron Primus accel-
erator was used. Planned dosage of radiation 
was 20 Gy applied in 10 fractions. The sched-
ule of ophthalmopathy was arranged in the 
treatment planning system. Each patient had 
a planning tumour volume (PTV) area pro-
jected (left PTV and right PTV containing 
retrobulbar area together with peribulbar 
muscles and critical organs, i.e. lenses and 
eyeballs). Evaluation of dose distribution in 
the treated area and critical organs was pos-
sible as a result of the use of dose volume his-
tograms (DVH) from the treatment planning 
system (Fig. 2). Execution of the treatment 
plan was controlled by in vivo measurements 
of doses using semiconducting, MOSFET type 
detectors. Dosage was controlled once during 
Fig. 1. System of beams and dose distribution durring irradiation of the retrobullar area in Graves Basedow disease
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the treatment. Detectors were placed under 
the patient’s mask on the left and right eyelid 
and on the mask in the middle of irradiated 
fi elds. The detected dose was compared to the 
planned dose read from the treatment plan-
ning system. Control of treatment quality was 
also performed by comparing portal images 
(created in every patient beginning irradia-
tion treatment) to images from the treatment 
planning system.
RESULTS
From among 121 patients treated 11 (9.1%) 
did not receive a planned treatment dosage. 
One patient (0.8%) irradiated up to the dose 
of 14 Gy/ 7 fractions did not report for further 
therapy. In 5 patients (4.1%) a dose of 16 Gy/ 
8 fractions was used and in another 5 (4.1%) 
a dose of 18 Gy/ 9 fractions (from the total, 
6 were due to prolonged device malfunction 
and 4 quitted treatment).
Fig. 2. Histogram obtained from the treatment planning system during irradiation of the retrobullar area in Graves Basedow 
disease
9 patients (7.4%) developed during the ir-
radiation treatment an acute post-radiation 
reaction. 3 patients (2.5%) experienced inten-
sifi ed lacrimation and swelling of the eyelids 
(one of the patients suffered from double vi-
sion as well), 2 (1.6%) had a slight skin erythe-
ma in areas subjected to high doses, 1 (0.8%) 
had intensifi ed lacrimation and deterioration 
of visual acuity, in 1 (0.8%) patient erythema 
was accompanied by a burning sensation of 
the eyeballs, in 1 (0.8%) slight lacrimation 
occurred and in another 1 (0.8%) intensifi ed 
double vision and deterioration of visual acu-
ity were present. Symptoms mentioned above 
were of transient character.
During the radiotherapy 10 patients (8.3%) 
reported improvement of local state (4 – in-
creased movement range of eyeballs, 3 – de-
creased exophthalmos, 2 – regression of 
diplopia and lacrimation and 1 – reduction of 
eyeball pain).
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In a control ophthalmological examination 
performed at 3, 6 and 12 months after irra-
diation, stabilization was noted in 21 patients 
(17.3%) and progression in 3 (2.5%). A further 
97 patients (80.2%) presented improvement 
in the form of reduction or total regression of 
ophthalmopathy symptoms.
As a result of DVH (dose volume histo-
grams) use from the treatment planning sys-
tem it was possible to check the dose distribu-
tion in the treated area and critical organs. It 
is presented in Table 1.
Table 1 analysis shows that the mean dose 
in the PTV area was: left PTV – 19.99 Gy and 
right PTV – 19.94 Gy. Taking into consider-
ation a dose which was planned for all the pa-
tients, it was possible to conclude that the left 
lens received a mean dose of 1.38 Gy and the 
right lens a mean dose of 1.34 Gy. The dose 
which is allowed for a lens is within the range 
of 6 – 8 Gy.
Analysis of dosimetric, in vivo measure-
ments shows that the mean dose calculated 
for 10 fractions of irradiation and measured 
by detectors placed on the eyelids was 0.7 Gy. 
The difference between the dose planned for 
lenses and the one achieved in measurements 
in vivo results from the fact that detectors are 
placed on the surface of the patient’s eyelids.
DISCUSSION
The course of Graves-Basedow disease and co-
existent ophthalmopathy is very variable. Even 
after several years of stabilization a recurrence 
of the disease is often observed [1, 38, 39]. The 
majority of patients experiences a spontaneous, 
idiopathic improvement [1, 38, 40].
Corticosteroids and irradiation of retrobul-
bar areas are still important elements of treat-
ment, blocking local infl ammatory reaction 
and stabilizing the disease process [41]. These 
methods lead to a reduction of existing symp-
toms in only 40-70% [42]. Therefore surgical 
treatment is often required [33, 41, 43, 45].
The aim of radiotherapy in the course of 
Graves-Basedow disease is to eliminate ra-
diosensitive lymphocytic infi ltrations of eye-
ball muscles and fi broblasts while preserving 
normal functions and anatomical structures 
localized inside the orbital cavity [21, 46]. Ef-
fi cacy of radiotherapy as an exclusive method 
of ophthalmopathy treatment in the course of 
Graves-Basedow disease is about 55-60% [47, 
48, 49]. According to various data total im-
provement is between 44% and 93% [2].
At least two clinical control trials prove 
that combining high-dose corticotherapy 
with irradiation treatment is most effective in 
treatment of malignant exophthalmos [1, 50, 
51, 52]. Corticosteroids can reduce the side 
effects of radiotherapy while radiotherapy re-
duces the frequency of relapses after steroid 
therapy [1, 18, 53].
Current indications for ophthalmopathy 
treatment with irradiation in the course of 
Graves-Basedow disease are: steroid-resistant 
exophthalmos, contraindications to steroid 
use, uncontrolled or progressing side effects 
during use of small steroid doses, progression 
of ophthalmic symptoms after surgical orbit 
decompression, and nagging symptoms from 
soft, peribulbar tissues [2, 38, 39, 40, 41]. Ra-
diotherapy should be used in patients older 
than 35, in a state of euthyreosis and with short 
areas dose[cGy]
maximal mean
Left PTV 2096 1999
Right PTV 2099 1994
Left lens 138 110
Right lens 134 113
Left eyeball 2010 998.2
Right eyeball 2023 988.5
Table 1. Dosage in areas (PTV, lenses, eyeballs) during the whole therapy in a group of 121 patients sub-
jected to radiotherapy (10 fractions per 2 Gy)
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duration of symptoms (<6 months; according 
to other authors <18 months) [2, 4, 24, 34, 42, 
43, 44]. In the case of ophthalmopathy in one 
eye (10% of cases in general) both retrobulbar 
areas should be irradiated [2]. It is not recom-
mended to use radiotherapy for cosmetic rea-
sons, in patients previously irradiated, in case 
of isolated exophthalmos or isolated dysfunc-
tion of oculomotor muscles with no signs of in-
fl ammation, spontaneous remission and in the 
case of diabetic retinopathy and other forms 
of diseases involving microvessels [2, 41]. In 
such situations surgery constitutes an elective 
treatment. Diabetes mellitus is a controversial 
contraindication to radiotherapy of the ret-
robulbar areas as it may increase the risk of 
retinopathy induced by radiotherapy [45, 46]. 
Other authors believe that diabetes mellitus is 
an indication for irradiation because a patient 
with diabetes mellitus is not a good candidate 
for steroid therapy or surgical methods [2].
The effi cacy of radiotherapy depends on 
factors such as: duration of symptoms (>6–12 
months), male gender, coexistent hyperthy-
roidism, and smoking. Their presence reduces 
the effects of therapy [24, 49, 65, 66, 67, 68]. 
Response to treatment occurs within the fi rst 
6 months after the end of therapy but an im-
provement may appear later [69, 70]. The most 
susceptible to radiotherapy are soft, perior-
bital tissues and oculomotor muscles. The per-
centage of responses is 50% to 80% [3, 7, 47, 71, 
72, 73, 74, 75, 76, 77].
Improvement of cornea damage and vision 
impairment reaches 71–75% [5, 71]. Radiother-
apy does not signifi cantly reduce exophthal-
mos or movement impairment of eyeballs [44, 
49, 76, 77, 79, 80, 81, 82, 83, 84].
Radiotherapy of the retrobulbar areas is gen-
erally believed to be a safe and well-tolerated 
treatment [3, 4, 5, 6, 7, 8, 9, 10, 44, 48, 56, 69, 
85]. In the discussed material an acute post-
radiation reaction was present in 11/121 (9.1%) 
and was of transient character. Complications 
of irradiating the retrobulbar areas present in 
the literature, including erythema of the eyelids, 
swelling of periorbital tissues and conjunctivas, 
headaches, loss of hair, and blurred vision, were 
also transient and mild [45, 59]. Late complica-
tions of irradiating retrobulbar areas are: retin-
opathy, neoplasms induced by irradiation and 
cataract [86, 87, 88, 89, 90, 91, 92]. 3 cases (2.5%) 
of cataract were reported after irradiation in the 
presented material and they were related to the 
physiological aging process rather than to radio-
therapy. Cataract was diagnosed before begin-
ning irradiation of malignant exophthalmos in 
patients older than 60. No diabetic retinopathy 
was noted in the group of patients with diabetes 
mellitus after combined therapy (9.9%). Second-
ary malignant neoplasms of a previously irradi-
ated area were not detected either.
Treatment of malignant exophthalmos is 
not fully satisfactory so far, so new methods of 
therapy are being researched. Great expecta-
tions are connected with the use of cytokine 
antagonists, especially pentoxifylline, soma-
tostatin analogues and colchicine. Trials re-
lated to these drugs are so far experimental 
[1, 11, 18, 44, 45, 93].
Currently the majority of centres point to a 
combination of glucocorticosteroids with irra-
diation as the best form of treatment [94, 95].
CONCLUSIONS
1. Radiotherapy is a well tolerated method 
of ophthalmopathy treatment in the course of 
Graves-Basedow disease.
2. The effi cacy of radiotherapy as an exclu-
sive method of malignant exophthalmos treat-
ment seems to be lower than that of irradiation 
combined with corticosteroid treatment.
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